The addition of Maraviroc (MVC), a CCR5 inhibitor, before infection (Day-1) restricted viral infection in both oMG and pMG, indicating specific viral entry via the CCR5 coreceptor (Figure 2A,B). This evidence concerns the gene CCR5 and viral infectious disease.